Copyright
©The Author(s) 2016.
World J Gastroenterol. Jan 28, 2016; 22(4): 1421-1432
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1421
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1421
Table 1 Recommendations for therapy in patients with genotype 1a
| Patient characterization | Recommended | Duration (wk) | Scientific evidence | Real-world evidence |
| Genotype 1a naive noncirrhotic | SOF + LDV | 12 | ION-1 | |
| SOF + LDV (CV < 6 × 106 UI/mL) | 8 | ION-3 | ||
| OBV + PTVR + DSV + RBV | 12 | SAPHIRE I PEARL | ||
| SOF + SIM | 12 | COSMOS | TARGET TRIO | |
| SOF + DCV | 12 | |||
| SOF + PEG + RBV | 12 | NEUTRINO | ||
| Genotype 1anaive cirrhotic | SOF + LDV | 12 | ION-1 | |
| OBV + PTVR + DSV + RBV | 12 | TURQUOISE-II PEARL | ||
| SOF + SIM | 12 | COSMOS | ||
| SOF + DCV | 12 | |||
| SOF + PEG + RBV | 12 | NEUTRINO | ||
| Genotype 1a retretated noncirrhotic | SOF + LDV | 12 | ION-2 | |
| OBV + PTVR + DSV + RBV | 12 | SAPHIRE-II | ||
| SOF + SIM | 12 | COSMOS | ||
| SOF + DCV | 12/24 | |||
| Genotipo 1a retreated cirrhotic | SOF + LDV + RBV | 12 | ION-2 | |
| SOF + LDV | 24 | ION-2 | ||
| OBV + PTVR + DSV + RBV | 12/24 | TURQUOISE-II PEARL | ||
| SOF + SIM | 12 | COSMOS | ||
| SOF + DVC | 24 |
Table 2 Recommendations for therapy in patients with genotype 1b
| Patient characterization | Recommended | Duration | Scientific evidence | Real-world evidence |
| Genotype 1b naive noncirrhotic | SOF + LDV | 12 | ION-1 | |
| SOF + LDV (CV < 6 × 106 UI/mL) | 8 | ION-3 | ||
| OBV + PTVR + DSV | 12 | SAPHIRE I PEARL | ||
| SOF + SIM | 12 | COSMOS | TARGET TRIO | |
| SOF + DCV | 12 | |||
| SOF + PEG + RBV | 12 | NEUTRINO | ||
| Genotype 1b naive cirrhotic | SOF + LDV | 12 | ION-1 | |
| OBV + PTVR + DSV + RBV | 12 | TURQUOISE-II PEARL | ||
| SOF + SIM | 12 | COSMOS | ||
| SOF + DCV | 12 | |||
| SOF + PEG + RBV | 12 | NEUTRINO | ||
| Genotype 1b retreated noncirrhotic | SOF + LDV | 12 | ION-2 | |
| OBV + PTVR + DSV | 12 | SAPHIRE-II | ||
| SOF + SIM | 12 | COSMOS | ||
| SOF + DCV | 12/24 | |||
| Genotype 1b retreated cirrhotic | SOF + LDV + RBV | 12 | ION-2 | |
| SOF + LDV | 24 | ION-2 | ||
| OBV + PTVR + DSV + RBV | 12 | TURQUOISE-II PEARL | ||
| SOF + SIM | 12 | COSMOS | ||
| SOF + DVC | 24 |
Table 3 Recommedation for therapy in patients with genotypes 2 and 3
| Patient characterization | Recommended | Duration (wk) | Scientific evidence |
| Genotype 2 naive noncirrhotic/cirrhotic | SOF + RBV | 12 | Fission positron |
| SOF + PEG + RBV | 12 | Lonestar-2 | |
| Genotype 2 retretated noncirrhotic | SOF + RBV | 12 | Fussion valence |
| SOF + PEG + RBV | 12 | Lonestar-2 | |
| Genotype 2 retreated cirrhotic | SOF + PEG + RBV | 12 | Lonestar-2 |
| SOF + RBV | 16 | Fussion valence | |
| Genotype 3 naive and retreated noncirrhotic/cirrhotic | SOF + RBV | 24 | Valence |
| SOF + PEG + RBV | 12 | Lonestar-2 | |
| SOF + LDV + RBV | 12 | Electron-2 | |
| SOF + DVC (No en cirróticos) | 12 | Ally-3 |
Table 4 Recommendations for therapy in patients with genotypes 4, 5 and 6
| Patient characterization | Recommended | Duration (wk) | Scientific evidence |
| Genotype 4 | SOF + PEG + RBV | 12 | Atomic neurino |
| SOF + LDV | 12 | Synergy | |
| SOF + RBV | 12 | Egyptian | |
| 24 | |||
| (cirrhotics and nulls responders) | |||
| OBV + PTV + RBV (noncirrhotics) | 12 | Pearl-1 | |
| Genotype 5 | SOF + PEG + RBV | 12 | Neutrino |
| Genotype 6 | SOF + PEG + RBV | 12 | Atomic |
| SOF + LDV | 16 | Electron-2 |
- Citation: González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol 2016; 22(4): 1421-1432
- URL: https://www.wjgnet.com/1007-9327/full/v22/i4/1421.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i4.1421